Royal London Asset Management
GCVRZ

Royal London Asset Management’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Royal London Asset Management’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-41,192
Closed -$36K – 669
2019
Q4 		$36K Sell
41,192
-2,885
-7% -$2.21K ﹤0.01% 636
2019
Q3 		$25K Hold
44,077
– – ﹤0.01% 655
2019
Q2 		$23K Hold
44,077
– – ﹤0.01% 534
2019
Q1 		$20K Hold
44,077
– – ﹤0.01% 656
2018
Q4 		$21K Hold
44,077
– – ﹤0.01% 662
2018
Q3 		$24K Hold
44,077
– – ﹤0.01% 511
2018
Q2 		$22K Buy
+44,077
New +$20.5K ﹤0.01% 578

Royal London Asset Management's GCVRZ Position: Q1 2020 in Review

Royal London Asset Management sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 41,192 shares — an estimated $36K sold.

Royal London Asset Management first reported a position in GCVRZ in Q2 2018 and held it in 7 quarters. The position peaked at $36K in Q4 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.

  • Royal London Asset Management reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
  • Royal London Asset Management sold 41,192 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $36K.
  • Royal London Asset Management first reported a position in Sanofi Contingent Value Rights in Q2 2018 and held it in 7 quarters.
  • Royal London Asset Management's Sanofi Contingent Value Rights position peaked at $36K in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.

Based on Royal London Asset Management's 13F filing for Q1 2020, filed 1 May 2020.